Europe ePRO, ePatient Diaries, and eCOA Market

Market Introduction

The usage of electronic Clinical Outcome Assessment (eCOA) is a push towards adapting to the ‘new normal’ as it is a method to gather patient data electronically through the use of technology such as smart home devices, handheld monitors, wearables, e-diaries, tablets and web servers to allow the stakeholders in the trials (patients, healthy volunteers, investigators and caregivers) to report outcomes directly and digitally. Although historically COA was only related to the evaluation of Patient-Related Outcomes (PRO), the FDA has now broadened the definition to include PerfO, ClinRO and ObsRO along with PRO. In simple terms, when the above parameters are reported electronically, they fit under the eCOA spectrum.

eCOA/ePRO platform has substantial benefits for sponsors and CROs, as it reduces administrative burden, mitigates cost, and speeds trials. Such a system shows strong results with fewer errors and discrepancies, improved data quality, clearer signals, and standardized, accurate studies. The increasing adoption of EHR, and government regulations mandating maintain health records is driving the growth of the market.

Thus, a growing demand for clinical trials is expected to create a significant demand for ePRO, ePatient Diaries, and eCOA in the coming years, which is further anticipated to drive the ePRO, ePatient Diaries, and eCOA market.

Short-term impacts of the COVID-19 pandemic include demand changes, revision in the regulatory process, changes in the research and development process, and the shift towards telecommunication and telemedicine. Moreover, the slowdown in market growth, delay in product approval, adoption of the self-sufficient pharm-production supply chain, and changes in the trend in consumption of health-market products and ethical dilemmas could be anticipated as long-term impacts of the COVID-19 pandemic on the pharmaceutical sector in both global and local levels. Market players in the market are launching new software platforms to boost electronic clinical trials to deal with a pandemic situation. For instance, In July 2020, Axiom Real-Time Metrics (“Axiom”), a leading provider of unified eClinical technologies and services, announced its collaboration with the University of Oxford on a large-scale clinical trial on COVID-19 preventative treatments. These factors had a potential impact on the Europe ePRO, e-Patient Diaries, and eCOA market.

Europe ePRO, ePatient Diaries, and eCOA Strategic Insights

Strategic insights for the Europe ePRO, ePatient Diaries, and eCOA provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe ePRO, ePatient Diaries, and eCOA Report Scope

Europe ePRO, ePatient Diaries, and eCOA Regional Insights

The geographic scope of the Europe ePRO, ePatient Diaries, and eCOA refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The ePRO, ePatient Diaries, and eCOA market in Europe is expected to grow from US$ 447.8 million in 2021 to US$ 1,184.3 million by 2028; it is estimated to grow at a CAGR of 14.9% from 2021 to 2028. Patient centricity means designing a treatment, clinical trial, or other health solution centered around the patient. Creating a patient-centric solution involves getting feedback from real patients and their loved ones and making decisions based on their needs and perspectives. Various clinical trials struggle with enrollment and patient retention. Not only do 80% of trials struggle with enrollment, but some studies estimate that up to 30% of patients who join a clinical trial end up dropping out.

Patient engagement is perhaps the most important when it comes to retaining trial participants. Considering the COVID-19 pandemic, with respect to running a clinical trial, researchers have been getting creative, trading traditional processes for virtual or decentralized opportunities. One of the major advantages of decentralized trials is that they minimize health risks for patients taking part, many of whom have conditions that make them especially vulnerable to COVID-19. This benefit removes the burden or any accompanying anxieties from patients and encourages participation from wherever they may be.

Key Market Segments

In terms of type of solution, the e-clinical outcome assessments segment accounted for the largest share of the Europe ePRO, ePatient Diaries, and eCOA market in 2020. In terms of modality, the mobile devices segment held a larger market share of the ePRO, ePatient Diaries, and eCOA market in 2020. In terms of end user, the cinical trial sponsors segment held a larger market share of the ePRO, ePatient Diaries, and eCOA market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the EPRO, ePatient Diaries, and eCOA market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are ERT Clinical, ArisGlobal LLC, The Diary Pte. Ltd, ICON PLC, PAREXEL INTERNATIONAL CORPORATION, Anju Software, Inc., Kayentis, Bracket Global LLC, Dassault Systèmes SE, and CRF Health.

Reasons to buy report

• To understand the Europe ePRO, ePatient Diaries, and eCOA market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe ePRO, ePatient Diaries, and eCOA market
• Efficiently plan M&A and partnership deals in Europe ePRO, ePatient Diaries, and eCOA market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe ePRO, ePatient Diaries, and eCOA market
• Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.

EUROPE EPRO, EPATIENT DIARIES, AND ECOA MARKET SEGMENTATION

By Type of Solution

• eClinical Outcome Assessments
• e-Patient Reported Outcomes
• Clinician Reported Outcomes
• Observer Reported Outcomes
• Performance Outcomes
• e-Patient Diaries

By Modality

• Computer
• Mobile Devices

By End User

• Clinical Trial Sponsors
• Contract Research Organizations
• Hospitals
• Academic Institutes
• Pharmaceutical Companies
• Others

By Country

• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Companies Mentioned

1. ERT Clinical             
2. ArisGlobal LLC       
3. The Diary Pte. Ltd                
4. ICON PLC                
5. PAREXEL INTERNATIONAL CORPORATION   
6. Anju Software, Inc.             
7. Kayentis                  
8. Bracket Global LLC              
9. Dassault Systèmes SE        
10. CRF Health